Introduction {#s1}
============

In recent years, the emergence of carbapenem-resistant *Enterobacteriaceae* (CRE) has become a serious issue both on community-acquired infections and healthcare-associated infections (van Duin and Doi, [@B19]). As well as other *Enterobacteriaceae, Enterobacter cloacae* (*E. cloacae*) is a conditional pathogen found in the intestine. Healthcare-associated infections caused by *E. cloacae* ranked third among all the *Enterobacteriaceae* (Dai et al., [@B1]). *Enterobacter cloacae* can produce chromosome mediated AmpC β-lactamase and has resistance to ampicillin, amoxicillin/clavulanic, cephamycin and first and second generation cephalosporin. A wide spectrum of antibacterial drugs such as carbapenems may be used in treatment more often. Thus, multidrug resistance has emerged rapidly under antibiotic selection pressure. Carbapenem-resistant *E. cloacae* infections have been reported in many countries such as Spain, Australia, the United States, India, and China (Kiedrowski et al., [@B6]; Fernández et al., [@B2]; Liu et al., [@B10]; Sidjabat et al., [@B17]). The emergence of carbapenem-resistant *E. cloacae* is an enormous challenge to clinical treatment. It is well known that the main mechanism for reduced susceptibility to carbapenems in *E*. *cloacae* is the deregulation of ACT (the natural cephalosporinase of *E*. *cloacae*), which is associated with a decrease in membrane permeability. In addition to this, producing carbapenemases is another important mechanism of *Enterobacteriaceae* in carbapenem resistance (Walsh et al., [@B21]; Nordmann et al., [@B11]; Tzouvelekis et al., [@B18]). Also, the mechanism of combinations of either ESBL or AmpC and mutation of porins may hold a certain proportion (Yang et al., [@B23]).

Up until now, there was a lack of multicenter research on carbapenem-resistant *E. cloacae* in China. So, we conducted this molecular epidemiological study on carbapenem-resistant *E. cloacae* to further understand the prevalence of the bacteria in China.

Materials and methods {#s2}
=====================

Sample collection
-----------------

From November 2012 to August 2016, we collected 55 unrepeated strains of carbapenem-resistant \[any carbapenem (imipenem, meropenem, or ertapenem) as determined by standard methods\] *E. cloacae* from 12 hospitals in 11 Chinese cities (Beijing, Chengde, Zunhua, Ji\'nan, Xuzhou, Xi\'an, Wuhan, Xiamen, Guangzhou, Dongguan, and Shenzhen; Figure [1](#F1){ref-type="fig"}). The participating hospitals include Peking University People\'s Hospital, Peking Union Medical College Hospital, Affiliated Hospital of Chengde Medical University, People\'s Hospital of Zunhua, Qilu Hospital of Shandong University, Affiliated Hospital of Xuzhou Medical University, Xijing Hospital, Tongji Hospital, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital Sun Yat-sen University, Donghua Hospital Sun Yat-sen University, and Shenzhen Second People\'s Hospital.

![Map of China showing the location of the 11 cities where the carbapenem-resistant *Enterobacteriaceae cloacae* isolates were collected.](fmicb-09-01597-g0001){#F1}

Identification of the bacterial strains and antimicrobial susceptibility tests
------------------------------------------------------------------------------

All isolates were identified with matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, Bremen, Germany). Minimum inhibitory concentrations (MICs) were determined by the agar dilution method according to CLSI guidelines (M100-S27). The tested drugs included ceftriaxone (Roche China, Shanghai, China), cefotaxime, ceftazidime, cefepime, aztreonam, amikacin, levofloxacin, minocycline, fosfomycin (National Institute for Food and Drug Control of China, Beijing, China), piperacillin/tazobactam, tigecycline (Pfizer, NY, USA), imipenem (Merck Sharp & Dohme, Hangzhou, China), meropenem (Sumitomo Pharmaceuticals, Suzhou, China), ciprofloxacin (Bayer, Leverkusen, Germany), and polymyxin B (Amresco, Solon, USA). Strains used in quality control were *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853. The results were interpreted according to 2017 CLSI standards (M100-S27). The tigecycline test was performed according to the Food and Drug Administration standards.

Detection of antimicrobial resistance genes
-------------------------------------------

Phenotypic screening for the resistance genes of carbapenem-resistant *E. cloacae* strains was based on the 2017 CLSI guidelines. Modified Hodge test (MHT), imipenem-EDTA double-disk synergy test (DDST) (Lee et al., [@B8]), and modified carbapenem inactivation method (mCIM) were used to test carbapenemase production. Polymerase chain reaction (PCR) was used to detect carbapenemase genes (*bla*~NDM~, *bla*~KPC~, *bla*~IMP~, *bla*~IMI~, *bla*~NMC~, *bla*~GES~, *bla*~SME~, *bla*~SIM~, *bla*~VIM~, and *bla*~OXA−48~) and other β-lactamase genes (*bla*~CTX−M~, *bla*~TEM~, *bla*~SHV~, *bla*~DHA~, and *bla*~CMY~) (Lewis et al., [@B9]; Yang et al., [@B23]). The products were submitted for sequencing.

Multilocus sequence typing (MLST)
---------------------------------

MLST was performed according to a previously described method (<https://pubmlst.org/ecloacae/>). New alleles and sequence types were submitted to the MLST website and approved. Sequence Type Analysis and Recombinational Tests 2 (START2) (<http://pubmlst.org/software/analysis/start2/>) software was used to generate the phylogenetic tree (Jolley et al., [@B5]).

Plasmid conjugation test
------------------------

The plasmid conjugation test was used to test carbapenem-resistant gene transfer. Ten strains were selected for the test. *Escherichia coli* EC600 (rifampicin resistant) was used as the recipient. Conjugants were screened using China blue lactose agar plates containing rifampicin (300 μg/ml) and imipenem (1 μg/ml). The donor and the recipient were mixed at a ratio of 1:1 for 24 h. Transconjugants were selected on China blue lactose agar plates (OXOID, Basingstoke Hampshire, UK), supplemented with rifampicin (100 μg/ml) and imipenem (1 μg/ml). PCR was used to screen for *bla*~NDM−1~, *bla*~VIM−1~, *bla*~KPC−2~, and *bla*~IMP−1~ as previously described (Wang et al., [@B22]).

Pulsed-field gel electrophoresis (PFGE)
---------------------------------------

*Enterobacter cloacae* isolates were characterized by PFGE according to the previously published protocol by Ribot et al., with modifications (Ribot et al., [@B14]). We selected 23 *bla*~NDM−1~-positive isolates (including the 15 isolates from Shenzhen, 6 isolates involved in the conjugation experiments, and another 2 representative isolates).

Electrophoresis conditions were altered to have an initial switch time of 2.16 s and a final switch time of 54.17 s, and gels were run for 18 h. The resulting PFGE patterns were analyzed in BioNumerics software (Applied Maths, Austin, TX, USA) with dendrograms based on the Dice coefficient with a band position tolerance of 1%. Patterns with no discernible differences were considered indistinguishable and given the same PFGE pattern designation.

S1-nuclease PFGE and southern blotting
--------------------------------------

S1-nuclease PFGE and Southern blotting were performed to estimate the size of plasmids harbored by *bla*~NDM−1~-positive strains as described previously. We selected 23 *bla*~NDM−1~-positive isolates as mentioned above.

The *bla*~NDM−1~ gene was detected by digoxigenin-labeled specific probes (DIG High Prime DNA Labeling and Detection Starter Kit II, Roche Diagnostics, Mannheim, Germany). *Salmonella enterica* H9812 was used as a size marker.

Statistical analyses
--------------------

WHONET (version 5.6) software (<http://www.whonet.org/software.html>) and SPSS (version 22.0) software (SPSS Inc., Chicago, IL, USA) were used for statistical analyses.

Ethical approval
----------------

This study was approved by the research ethics board at Peking University People\'s Hospital. Informed consent was not needed as this study was retrospective and participants were anonymized. Medical records and patient\'s information were retrospectively reviewed and collected.

Results {#s3}
=======

Characteristics of collected samples
------------------------------------

The most common specimens were respiratory tract (20 cases, 36.4%), followed by urine (13 cases, 23.6%), blood (11 cases, 20%), ascitic fluid (7 cases, 12.7%), bile (2 cases, 3.6%), catheter (1 case, 1.8%), and wound (1 case, 1.8%).

Antimicrobial susceptibility tests
----------------------------------

Of all the antimicrobials tested, the most susceptible antimicrobial was polymyxin B (100%, 55/55), followed by amikacin (89.1%, 49/55), fosfomycin (80%, 44/55), tigecycline (78.2%, 43/55), minocycline (52.7%, 29/55), levofloxacin (30.9%, 17/55), and ciprofloxacin (25.5%, 14/55). All of the 36 *bla*~NDM~-positive strains were resistant to piperacillin-tazobactam, ceftazidime, cefotaxime, ceftriaxone, cefepime, imipenem, and meropenem. It is worth noting that the most susceptible antimicrobials to *bla*~NDM~-positive strains was polymyxin B (100%, 36/36), followed by amikacin (86.1%, 31/36), and fosfomycin (86.1%, 31/36). There was some differences between *bla*~NDM~-positive strains and strains with other carbapenemases (Table [1](#T1){ref-type="table"}).

###### 

*In vitro* activities of antimicrobial agents against carbapenemase-producing *Enterobacteriaceae*.

  **Antimicrobials**        **All isolates (*****n*** = **55)**   **Isolates with** ***bla***~**NDM**~ **(*****n*** = **36)**   **Isolates with other carbapenemase genes except** ***bla***~**NDM**~ **(*****n*** = **14)**   **Comparison between the two groups**                                                   
  ------------------------- ------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------- ------- ------- ------ ------- ------- -------- ----------
  Piperacillin/tazobactam   20                                    256                                                           \>256                                                                                          0                                       \>256   \>256   64.3   8       128     25.451   \< 0.001
  Ceftazidime               1.8                                   \>256                                                         \>256                                                                                          0                                       \>256   \>256   7.1    256     \>256   --       0.265
  Cefotaxime                1.9                                   \>256                                                         \>256                                                                                          0                                       \>256   \>256   7.1    64      \>256   --       0.286
  Ceftriaxone               1.9                                   \>256                                                         \>256                                                                                          0                                       \>256   \>256   7.1    32      \>256   --       --
  Cefepime                  1.8                                   64                                                            128                                                                                            0                                       128     128     7.1    8       64      --       --
  Aztreonam                 17.4                                  256                                                           \>256                                                                                          6.7                                     256     \>256   50     4       256     6.003    0.014
  Imipenem                  12.7                                  8                                                             32                                                                                             0                                       8       32      42.9   2       4       --       0.001
  Meropenem                 16.4                                  8                                                             32                                                                                             0                                       8       64      57.1   1       4       --       0.019
  Amikacin                  89.1                                  4                                                             \>256                                                                                          86.1                                    4       \>256   100    2       8       0.781    0.377
  Ciprofloxacin             25.5                                  32                                                            128                                                                                            13.9                                    32      128     50     1       128     --       0.011
  Levofloxacin              30.9                                  16                                                            128                                                                                            22.2                                    32      128     50     2       32      1.704    0.192
  Fosfomycin                80                                    16                                                            128                                                                                            86.1                                    8       128     75     16      256     --       0.19
  Minocycline               52.7                                  16                                                            128                                                                                            30.6                                    32      128     57.1   4       32      4.276    0.039
  Polymyxin B               100                                   0.125                                                         0.25                                                                                           100                                     0.125   0.25    100    0.125   0.25    --       --
  Tigecycline               78.2                                  1                                                             8                                                                                              72.2                                    1       8       91.7   1       1       0.838    0.36

Genotype analysis
-----------------

Among the 55 strains, 50 were confirmed to produce 8 types of carbapenemases including NDM-1, NDM-5, IMP-4, IMP-26, IMP-1, KPC-2, and VIM-1. The corresponding numbers of the strains that produced the foregoing types of carbapenemases were 34, 2, 6, 3, 2, 2, and 1. Other carbapenemase genes were not detected. No strains contained two or more carbapenemase genes. NDM-1-producing carbapenem-resistant *E. cloacae* was primarily distributed in Shenzhen (Table [2](#T2){ref-type="table"}). Carbapenemase genes were not detected in the other 5 strains.

###### 

Microbiological and molecular characteristics of 34 *bla*~NDM−1~-positive *Enterobacter cloacae* strains.

  **Isolate**   **Date of isolation**   **City**    **Gender/Age (Year)**   **Ward**                **Specimen**   **mCIM (mm)**   **MHT**   **EDTA-DDST**   **DHA**   **CTX-M**   **ST**   **PFGE pattern**   **Plasmid size, harboring *bla*~NDM~ (kb)**
  ------------- ----------------------- ----------- ----------------------- ----------------------- -------------- --------------- --------- --------------- --------- ----------- -------- ------------------ ---------------------------------------------
  ecl408        2015/6/8                Dongguan    M/24                    ICU                     ur             6               \+        \+              --        --          418      --                 --
  ecl409        2015/3/28               Dongguan    M/47                    ICU                     ur             6               \+        \+              --        --          418      --                 --
  ecl411        2015/6/25               Dongguan    F/49                    ICU                     ur             6               \+        \+              DHA-1     --          418      --                 --
  cas471        2015/12/28              Zunhua      M/36                    ICU                     ur             6               \+        \+              --        CTX-M-3     920      F                  \~54
  ecl497        2015/6/16               Ji\'nan     F/59                    Outpatient              sp             6               \+        \+              DHA-1     CTX-M-3     51       G                  \~52
  ecl645        2014/5/23               Guangzhou   F/66                    Neurology               ur             6               \+        \+              --        CTX-M-3     93       --                 --
  ecl759        2015/1/28               Shenzhen    F/60                    Hepatobiliary surgery   dr             6               ±         \+              DHA-1     --          88       B                  \~52
  ecl760        2015/2/6                Shenzhen    F/60                    Hepatobiliary surgery   wd             6               \+        \+              DHA-1     --          88       B                  \~52
  ecl766        2015/5/22               Shenzhen    M/77                    Respiratory             ca             6               \+        \+              DHA-1     --          93       C                  \~52
  ecl767        2015/5/22               Shenzhen    M/77                    Respiratory             bl             6               \+        \+              --        --          93       C                  \~52
  ecl768        2015/6/8                Shenzhen    M/47                    Neurosurgery            sp             6               \+        \+              --        --          418      A                  \~52
  ecl771        2015/6/18               Shenzhen    F/45                    Neurosurgery            sp             6               \+        \+              --        --          418      A                  \~52
  ecl774        2015/8/28               Shenzhen    F/61                    Neurosurgery            ur             6               \+        \+              --        --          418      A                  \~52
  ecl776        2015/9/14               Shenzhen    M/38                    Neurosurgery            ur             6               \+        \+              --        --          418      A                  \~52
  ecl777        2015/10/20              Shenzhen    M/34                    Neurosurgery            sp             6               \+        \+              --        --          93       D                  \~52
  ecl778        2015/11/22              Shenzhen    M/83                    Neurosurgery            ur             6               \+        \+              --        --          93       D                  \~52
  ecl779        2015/12/8               Shenzhen    F/42                    EICU                    sp             6               \+        \+              --        --          418      A                  \~52
  ecl780        2015/12/21              Shenzhen    M/70                    Neurosurgery            sp             6               \+        \+              --        --          93       E                  \~54
  ecl782        2015/12/18              Shenzhen    F/42                    EICU                    ur             6               \+        \+              --        --          418      A                  \~52
  ecl784        2015/12/25              Shenzhen    M/84                    Nephrology              bl             6               \+        \+              --        --          418      A                  \~52
  ecl786        2016/1/8                Shenzhen    F/42                    EICU                    ba             6               \+        \+              --        --          418      A                  \~52
  ecl828        2015/1/11               Xuzhou      M/55                    EICU                    sp             6               \+        \+              DHA-1                 51       --                 --
  ecl830        2015/1/23               Xuzhou      M/40                    Neurosurgery            sp             6               \+        \+              --        CTX-M-3     51       --                 --
  ecl844        2015/12/22              Xuzhou      M/77                    EICU                    sp             6               \+        \+              --        CTX-M-3     51       H                  \~52
  ecl886        2015/5/8                Xiamen      M/85                    ICU                     ab             6               \+        \+              --        --          171      I                  \~52
  ecl932        2016/5/27               Xiamen      M/61                    Urology Surgery         ur             6               \+        \+              --        --          78       --                 --
  ecl979        2016/6/26               Wuhan       M/46                    ICU                     ur             6               \+        \+              --        --          78       J                  \~58
  ecl982        2016/5/31               Xi\'an      F/57                    Hepatobiliary surgery   dr             6               \+        \+              --        --          78       --                 --
  ecl1017       2016/7/3                Beijing     F/35                    Respiratory             bl             6               \+        \+              --        --          121      K                  \~56
  ecl1028       2016/8/28               Beijing     F/59                    Hematology              sp             6               \+        \+              --        --          127      --                 --
  ecl1045       2016/4/26               Xuzhou      M/59                    Urology Surgery         bl             6               \+        \+              --        CTX-M-3     78       --                 --
  ecl1102       2016/6/22               Xuzhou      M/68                    ICU                     bl             6               \+        \+              --        --          231      --                 --
  ecl1115       2016/6/13               Xuzhou      M/74                    ICU                     sp             6               \+        \+              --        CTX-M-3     97       L                  \~52
  ecl1127       2016/7/27               Xuzhou      M/50                    EICU                    sp             6               \+        \+              DHA-1     CTX-M-14    97       M                  \~55

*ecl, Enterobacter cloacae; cas, Enterobacter asburiae; ICU, intensive care unit; EICU, emergency intensive care unit; ba, broncho-alveolar lavage; bl, blood; ca, catheter; dr, drainage; sp, sputum; ur, urine; wd, wound; EDTA-DDST, EDTA double-disk synergy test*.

NDM-1-producing *E. cloacae* isolates were mainly collected from Shenzhen (44.1%, 15/34), followed by Xuzhou (20.6%, 7/34), Beijing, Dongguan, Guangzhou, Ji\'nan, Xi\'an, Xiamen, Wuhan, and Zunhua. These samples were primarily collected from the Intensive Care Unit and the Emergency Intensive Care Unit (41.2%, 14/34), followed by the department of neurosurgery (23.5%, 8/34). NDM-1-producing *E. cloacae* isolates were most commonly identified in sputum samples (35.3%, 12/34), followed by urine samples (32.4%, 11/34). All strains were positive for MHT, imipenem-EDTA-DDST, and mCIM. Results of the three tests were consistent. In addition, 6 strains also produced the AmpC enzyme DHA-1, 8 strains produced CTX-M-3, and 2 strains produced both CTX-M and DHA-1.

MLST
----

The results of the MLST are shown in Figure [2](#F2){ref-type="fig"}. A total of 24 sequence types were detected in the 55 *E. cloacae* strains. ST418 was the most common (20%, 11/55), followed by ST93 (14.5%, 8/55).

![Multilocus sequence typing (MLST) phylogenetic tree of the 55 carbapenem-resistant *E. cloacae* strains. ab, abdominal fluid; ba, broncho-alveolar lavage.](fmicb-09-01597-g0002){#F2}

Plasmid conjugation test
------------------------

Plasmids from 9 carbapenemase-producing *E. cloacae* strains were successfully transferred to *E. coli* EC600. Drug sensitivity tests showed the MICs of meropenem increased by 5- to 8-fold in the 9 conjugators; for imipenem, cefepime, ceftazidime, and piperacillin/tazobactam, the MICs increased by 3\~6-, 7\~11-, 7\~10-, and 3\~7-fold, respectively (Table [3](#T3){ref-type="table"}).

###### 

Antibiotic susceptibilities of *E. cloacae* isolates and their transconjugants (μg/ml).

  **Isolate**                                **City**    **Carbapenemase**   **ST**   **MEM**   **IMP**   **FEP**   **CAZ**   **TZP**   **ATM**   **AMK**   **CIP**      **LVX**      **PB**   **TGC**
  ------------------------------------------ ----------- ------------------- -------- --------- --------- --------- --------- --------- --------- --------- ------------ ------------ -------- ---------
  ***E. cloacae*** **isolates**                                                                                                                                                                
  cas471                                     Zunhua      NDM-1               920      8         16        64        \>256     \>256     256       8         16           16           0.25     1
  ecl497                                     Ji\'nan     NDM-1               51       8         4         32        \>256     256       \>256     \>256     2            2            0.25     1
  ecl591                                     Guangzhou   VIM-1               175      0.5       4         8         256       128       0.032     1         \< = 0.016   \< = 0.016   0.125    0.5
  ecl763                                     Shenzhen    KPC-2               53       0.5       4         4         8         256       128       1         4            8            0.25     0.5
  ecl844                                     Xuzhou      NDM-1               51       2         8         16        \>256     128       128       4         0.25         0.5          0.125    0.5
  ecl886                                     Xiamen      NDM-1               171      2         4         32        \>256     256       128       1         2            2            0.5      1
  ecl979                                     Wuhan       NDM-1               78       \>32      \>32      \>256     \>256     \>256     --        1         \>64         64           0.25     4
  ecl1017                                    Beijing     NDM-1               121      8         8         64        \>256     \>256     --        2         64           16           0.125    0.5
  ecl1025                                    Beijing     IMP-1               78       2         2         32        \>256     8         --        0.5       32           32           0.125    0.25
  ***E. coli*** **transconjugant strains**                                                                                                                                                     
  471TC                                                  NDM-1                        2         8         32        \>256     256       128       1         0.125        0.5          0.25     0.125
  497TC                                                  NDM-1                        4         8         32        \>256     128       128       1         0.125        0.25         0.125    0.125
  591TC                                                  VIM-1                        2         4         128       \>256     \>256     0.25      1         0.125        0.25         0.125    0.125
  763TC                                                  KPC-2                        4         4         8         32        \>256     \>256     1         2            2            0.125    0.125
  844TC                                                  NDM-1                        2         8         16        \>256     128       64        1         0.125        0.25         0.125    0.25
  886TC                                                  NDM-1                        2         8         16        \>256     128       128       1         0.125        0.25         0.125    0.25
  979TC                                                  NDM-1                        4         8         16        \>256     128       4         0.125     2            4            0.125    2
  1017TC                                                 NDM-1                        8         16        128       \>256     256       \>256     2         0.125        1            0.125    0.125
  1025TC                                                 IMP-1                        1         2         32        \>256     16        0.125     1         0.125        0.25         0.25     0.125
  EC600                                                  --                           0.032     0.25      0.064     0.25      2         0.125     1         0.125        0.25         0.25     0.25

*MEM, meropenem; IMP, imipenem; FEP, cefepime; CAZ, ceftazidime; TZP, piperacillin/tazobactam; ATM, aztreonam; AMK, amikacin; CIP, ciprofloxacin; LVX, levofloxacin; PB, polymyxin B; TGC, tigecycline; TC, transconjugant strain; EC600, recipient strain*.

PFGE, S1-nuclease PFGE and southern blotting
--------------------------------------------

When typed by PFGE to determine if they were related, the 23 isolates yielded 13 PFGE patterns, which were designated as type A--M. Eight isolates (ecl768, ecl771, ecl774, ecl776, ecl779, ecl782, ecl784, and ecl786) obtained from Shenzhen had the same PFGE pattern (type A) and the remaining 15 isolates belonged to the other 12 PFGE patterns (type B--M) (Table [2](#T2){ref-type="table"}). The observation that 8 of the 15 *bla*~NDM−1~-positive *E. cloacae* isolates with the same PFGE pattern (type A) and the same sequence type (ST418) suggested a transmission outbreak of a common strain.

The results of S1-nuclease PFGE and Southern blotting showed that the plasmids harboring the *bla*~NDM−1~ gene ranged in size from approximately 52--58 kilobases, respectively (Table [2](#T2){ref-type="table"}). The plasmids harboring the *bla*~NDM−1~ gene of the 8 isolates obtained from Shenzhen were the same size (approximately 52 kilobases).

Discussion {#s4}
==========

Carbapenemase-producing *E. cloacae* has been reported in many countries, such as strains producing OXA-48 and VIM-1 have been reported in Spain. In Brazil, Australia and America, strains producing NDM-1, IMP-4, and KPC-3, respectively, have been reported (Kiedrowski et al., [@B6]; Rozales et al., [@B15]; Villa et al., [@B20]; Fernández et al., [@B2]; Sidjabat et al., [@B17]), while in Chongqing, Henan and Ningxia of China, strains producing NDM-1 have been identified (Dai et al., [@B1]; Liu et al., [@B10]; Shi et al., [@B16]). Strains that produced other carbapenemases have also been reported in the Sichuan province of China (Huang et al., [@B4]). In the present study, we found that the *E. cloacae* prevalent in China mainly produced NDM-1 (68.0%, 34/50) and IMP-4 (12.0%, 6/50). NDM-1 was found in the highest proportion and may represent a significant drug-resistant mechanism of carbapenem-producing *Enterobacteriaceae* in China.

The plasmid conjugation test was completed with 6 *bla*~NDM−1~-positive strains. Conjugants were all detected to have the *bla*~NDM−1~. Susceptibility results showed that compared with the receptor bacteria EC600, the conjugants have a higher MIC value on cephalosporins and carbapenems. There were no MIC promotions on polymyxin B and tigecycline between conjugants and EC600. Many studies have demonstrated that the plasmid owned *bla*~NDM~ also have other resistant genes, such as *bla*~TEM−1~, *bla*~CMY~, qnrA6, and qnrB1 for quinolone resistance, armA, rmtA, and rmtC for aminoglycoside resistance (Poirel et al., [@B12],[@B13]; Kocsis et al., [@B7]). But all strains in this study have no *bla*~TEM−1~ and *bla*~CMY~. Five of the conjugants have no MIC difference on quinolone with the EC600. Maybe the relative plasmid did not harbor the quinolone resistant gene.

MLST showed subtype diversity. A total of 24 sequence types were detected in 55 *E. cloacae* strains. ST418 was detected the most frequently (11/55, 20%), and the second was ST93 (14.5%, 8/55). Three new sequence types were found, namely ST916, ST919, and ST920. Our study reveals the diversity of carbapenem-resistant *E. cloacae* and the difference in genetic affinity, which is consistent with the study of Gomez-Simmonds et al. ([@B3]). Our study showed that ST418 is the main epidemic strain in Shenzhen in China; while in America, Central de Asturias of Spain, and the Henan province of China, the main epidemic strains were ST171, ST74, and ST120, respectively (Fernández et al., [@B2]; Liu et al., [@B10]; Gomez-Simmonds et al., [@B3]). We found that ST418 was genetically closer to ST127 and ST755 with START2 analysis. Studies have found that all ST418 strains produced NDM-1 carbapenemase, indicating that there might be a small outbreak of NDM-1-ST418 carbapenem-resistant *E. cloacae* in Shenzhen and Dongguan City of Guangdong province of China. In this study, ST78-NDM-1-type carbapenem-resistant *E. cloacae* was also found in Xuzhou, Xi\'an, Wuhan, and Xiamen, which should be taken seriously concern.

In conclusion, our study indicates that ST418, which produces NDM-1 carbapenemase, is the main epidemic strain of carbapenem-resistant *E. cloacae* in Shenzhen and Dongguan City of China. Early detection and monitoring are necessary to prevent the further spread of the bacteria.
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